Get started
Work

155P Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

Year: 2024
Type: article
Abstract: The use of immune checkpoint inhibitors (ICI) in a neoadjuvant or perioperative treatment concept emerges as a new standard for patients with resectable stage III NSCLC. There are however concerns about patients who cannot undergo definitive surgery after neoadjuvant treatment.
Source: ESMO Open
DOI: 10.1016/j.esmoop.2024.102910
Authors: S. Cardoso Almeida, S. Schaer, S. Hayoz, M. Guckenberger, T. Finazzi, I. Opitz, S. Schmid, M.T. Mark, A. Addeo, L.A. Mauti, D.C. Betticher, H-B. Ris, R. Stupp, A. Curioni-Fontecedro, S. Peters, M. Frueh, S.I. Rothschild, M. Pless, D. König
Institutions: Kantonsspital Winterthur, Swiss Group For Clinical Cancer Research, University Hospital Zurich, University Hospital of Basel, University Hospital of Bern, Kantonsspital Graubünden, University Hospital of Geneva, HFR Freiburg Kantonsspital, Hôpital du Valais, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Centre Hospitalier Universitaire Vaudois, Kantonsspital St. Gallen, Kantonsspital Baden
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4393152367
FWCI: 0.581
Cites:
Cited by: 2
Related to: 10